The purpose of the present invention is to provide a prophylactic or therapeutic agent for cancer pain. The present invention provides a pharmaceutical composition for preventing or treating cancer pain, the composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [In the formula, m is an integer of 1-4; and R1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1-3 halogen atoms, a methoxy group optionally substituted with 1-3 halogen atoms, and a methylthio group optionally substituted with 1-3 halogen atoms.]
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided is a dexmedetomidine-containing non-aqueous external preparation being capable of suppressing the precipitation of a crystal of dexmedetomidine in the preparation, and having satisfactory transdermal absorbability. The non-aqueous external preparation includes: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10 to 12 carbon atoms; (C) a propylene glycol monoester of a fatty acid having 6 to 16 carbon atoms; (D) an organic acid; and (E) an organic acid salt.
A cytotoxicity suppressant by phosaprepitant injection dilute solution having as an active ingredient glucose in an amount effective for isotonization.
Provided is an aqueous solution agent for a fosaprepitant injection, the aqueous solution containing a fosaprepitant and a diethylenetriamine pentaacetic acid.
[Problem] The present invention addresses the problem of providing a jelly preparation containing levocarnitine at a high concentration. The present invention also addresses the problem of providing a levocarnitine-rich jelly preparation for use in drugs, (1) which is reduced in adverse side effects on a patient who is subjected to the restriction of the intake of water or an energy (more specifically, the restriction of the intake of a nutrient such as a protein, water, an energy (calorie), common salt, and a mineral including potassium and phosphorus), i.e., a patient who should take account of the "Dietary Recommendations" edited by Japanese Society of Nephrology such as a patient affected by a renal disease, in order to allow the patient to ingest levocarnitine efficiently and safely, (2) which is easy to ingest, and/or (3) which has excellent physical properties and storage stability. [Solution] The problem can be solved by a jelly preparation containing levocarnitine at a high concentration, the jelly preparation having a specified composition.
To provide a nonaqueous external preparation comprising dexmedetomidine in which the crystallization of dexmedetomidine in the preparation is suppressed and which has excellent percutaneous absorbability. A nonaqueous external preparation that comprises: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10-12 carbon atoms; (C) a propylene glycol mono-ester of a fatty acid having 6-16 carbon atoms; (D) an organic acid; and (E) an organic acid salt.
The present invention addresses the problem of providing an oral pharmaceutical composition that (1) has reduced bitterness of levetiracetam of which a single dose is a large amount, (2) provides good ingestion feeling, and/or (3) has a favorable elutability. The present invention provides a gel oral pharmaceutical composition containing levetiracetam, which is an active ingredient, a gelling agent, a sweetening agent, and a pH adjusting agent and having a pH of about 6-7.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
8.
ACIDIC EMULSION COMPOSITION CONTAINING LOCAL ANESTHETIC AGENT
The purpose of the present invention is to provide a local anesthetic agent-containing composition that is (1) fast-acting after administration without being made to be sustained release and that has a lasting drug efficacy, and/or that has (2) good storage stability. Provided is an acidic emulsion composition containing a local anesthetic agent and a glyceride in which a fatty acid having 6 to 12 carbon atoms is ester bonded to a glycerin.
The present invention provides a rocuronium preparation with an excellent stability. The rocuronium preparation contains rocuronium and a buffer solution and having an adjusted pH of 3.5 or less (for example, 2.5 to 3.5). The buffer solution may be a citric acid-sodium hydroxide buffer solution, a tartaric acid-sodium hydroxide buffer solution, a potassium hydrogen phthalate-hydrochloric acid buffer solution, a glycine-hydrochloric acid buffer solution, or the like. Such a rocuronium preparation has, for example, after 6-month storage at 40° C., a generation rate of rocuronium-related substance C of 5% or less.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Provided is a patch providing sufficiently high absorbability of dexmedetomidine and less skin irritation.
Hydrous adhesive patch comprising dexmedetomidine or a salt thereof and a water-soluble polymer.
Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same
Provided is a rocuronium preparation designed to reduce vascular pain to be induced. The rocuronium preparation contains rocuronium and a buffer solution, and has titratable acidity of 100 mEg or less. The buffer solution may be an acetate buffer solution, a citrate buffer solution, a formate buffer solution, a tartrate buffer solution, a phosphate buffer solution, a glycine-hydrochloric acid buffer solution, or a citric acid-phosphate buffer solution.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Provided are: a method for industrially advantageously producing a high-purity pentapeptide; and a production intermediate thereof. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents an alkyl group or an aralkyl group.)
The present invention provides a rocuronium formulation having excellent stability. This formulation includes rocuronium and a buffer solution, and has a pH adjusted to 3.5 or less (for example, 2.5-3.5). The buffer solution may be a citric acid/sodium hydroxide buffer solution, a tartaric acid/sodium hydroxide buffer solution, a potassium hydrogen phthalate/hydrochloric acid buffer solution, a glycine/hydrochloric acid buffer solution or the like. This type of rocuronium formulation has a rocuronium analog C generation rate of 5% or less after being stored for six months at 40 °C, for example.
The present invention provides an emulsion composition of excellent physical stability over time and suitable safety, which is usable in concentration-increase applications, and characterized by the inclusion of sevoflurane, a fatty acid glyceride, and a hydroxyethyl starch.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Provided is an adhesive patch that exhibits sufficiently high dexmedetomidine absorbency and little dermal irritation. The water-containing adhesive patch contains a water soluble polymer and dexmedetomidine or a salt thereof.
Provided is a rocuronium preparation that makes it possible to suppress vascular pain. This rocuronium preparation is characterized by containing rocuronium and a buffer and having titratable acidity of 100 mEq or less. The buffer may be an acetate buffer, citrate buffer, formate buffer, tartrate buffer, phosphate buffer, glycine-hydrochloric acid buffer, citrate-phosphate buffer, or the like.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
The hand hygiene moment measuring system of the present invention includes a subject sensing device (2) to sense a subject's position and posture, a movement sensing device (3) to sense a subject's movement, a storage unit (4) to store particular combinations corresponding to hand hygiene opportunities, and a counter (5) to count a number of times combinations of a sensing information of the subject sensing device, a sensing information of the movement sensing device, and an object position information indicating a position of an object, achieved the combinations stored in the storage unit.
The purpose of the present invention is to provide an aripiprazole oral pharmaceutical preparation which has limited acidity and bitterness, poses little burden to the patient when administered, and is highly elutable, and for which the patient himself can readily confirm administration. The present invention pertains to an oral pharmaceutical preparation characterized by containing aripiprazole and a gelling agent, the pH being 4.6 or higher.
The purpose of the present invention is to provide a general anesthetic medicine which can prevent and/or alleviate an anesthetic-induced neuropathy in the brain (preferably the developing brain). The present invention relates to a medicine which can prevent and/or alleviate an anesthetic-induced neuropathy in the brain (preferably the developing brain), said medicine comprising a combination of a general anesthetic drug and hydrogen.
A61K 31/08 - Ethers or acetals acyclic, e.g. paraformaldehyde
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Provided is a stabilizer of acetaminophen in an aqueous composition, containing glycine. The stabilizer is more effective by further containing at least one kind of sulfites that is selected from the group consisting of sodium sulfite, potassium sulfite, and potassium pyrosulfite. The stabilization includes prevention of precipitation.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Disclosed are an external preparation for skin for improving wrinkles and sagging, an external preparation for skin for moisture retention, an external preparation for skin for promoting wound healing and an external preparation for lips, each of which contains raspberry ketone or a pharmaceutically acceptable salt thereof as an active ingredient.
A disinfectant which contains the following ingredients (a), (b), (c) and (d) and is free from other bactericidal disinfectants for sterilization: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture of both based on the whole disinfectant, (b) 0.1 to 2% (w/w) of lactic acid based on the whole disinfectant, (c) 0.01 to 2% (w/w) of citric acid based on the whole disinfectant, and (d) 0.001 to 0.1% (w/w) of a zinc compound capable of releasing zinc ions in a solution based on the whole disinfectant.
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
Disclosed is a sterilizing/disinfecting composition characterized by containing the following components (a), (b) and (c). (a) at least one alcohol selected from the group consisting of ethanol and isopropanol (b) at least one carboxyvinyl polymer selected from the group consisting of polyacrylic acids, polyacrylic acid salts, copolymers of polyacrylic acids and polyacrylic acid alkyl esters and copolymers of polyacrylic acid salts and polyacrylic acid alkyl esters (c) agar
It is intended to provide an external preparation for skin which improves coarsening of skin texture, wrinkles and sagging skin. The external preparation for skin of the invention is characterized by containing nonylic acid vanillylamide at 0.0001% by mass or more and 0.05% by mass or less based on the total of external preparation for skin as an active ingredient and is useful for improving coarsening of skin texture, wrinkles and sagging skin.
Disclosed is a bactericidal disinfectant ointment containing 0.1-4% by mass of at least one substance selected from the group consisting of chlorhexidine and salts thereof and 8-25% by mass of a hydrocarbon alcohol having 2-3 carbon atoms. The bactericidal effect of this disinfectant ointment approved by hand disinfection test continues at least 6 hours.
(i) A gel composition for sterilization containing 0.2-0.55 w/v% of at least one substance selected from the group consisting of chlorhexidine and salts thereof, 50-99 v/v% of a hydrocarbon alcohol having 2-3 carbon atoms, a thickening agent and a wetting agent, while having a viscosity of 10-1000 mPs. (ii) A gel composition for sterilization containing 0.2-0.55 w/v% of at least one substance selected from the group consisting of chlorhexidine and salts thereof, 50-99 v/v% of a hydrocarbon alcohol having 2-3 carbon atoms, 0.05-10 w/v% of a thickening agent and 0.15-10 w/v% of a wetting agent.
patents
